The comparison of hydroquinone and Melfade in the treatment of melasma

Randomized comparative clinical trial of hydroquinone 2% and Melfade for the treatment of melasma

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138809212840N1

Enrollment

Registered

2010-01-25

Start date

2008-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melasma. Chloasma

Interventions

Intervention 1: Intervention group: Melfade cream , 1 time/day on the lesion. Intervention 2: Control group: hidroqinone cream 2%, one time/day on the lesion.

Treatment - Drugs

Intervention group: Melfade cream , 1 time/day on the lesion

Control group: hidroqinone cream 2%, one time/day on the lesion

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: woman with physician diagnosed melasma. Exclusion criteria: history of the consumption of steroid, Melfade and hydroqinone drugs in recent 30 days, pregnancy, lactation, present history of OCP drug consumption.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Faint-colored of scar. Timepoint: 12 weeks. Method of measurement: observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Roksana Yaghmaee

Kurdistan University of Medical Sciences

ryaghmaee@muk.ac.ir+98 87 1328 5913

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026